Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease

Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease

ObjectiveIn this study, our objective was to provide practice recommendations by thoroughly examining lifestyle interventions for adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD). This was achieved through a systematic review of the literature, specifically focu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mei-jing Chen, Ying Chen, Jin-qing Lin, Rong Hu, Dun Liu, Jing-yi Chen, Ka Li, Xiao-ying Jiang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Nutrition
Subjects:	evidence-based nursing evidence summary lifestyle intervention metabolic dysfunction-associate fatty liver disease non-alcoholic fatty liver disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fnut.2024.1421386/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

The impact of fasting on cardiovascular risk control in patients with metabolic dysfunction-associated steatotic liver disease
by: Anna E. Płatek, et al.
Published: (2023-09-01)

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

Complement 3a receptor 1 on macrophages and Kupffer cells is not required for the pathogenesis of metabolic dysfunction-associated steatotic liver disease
by: Edwin A Homan, et al.
Published: (2025-01-01)

Metabolic dysfunction-associated steatotic liver disease
by: Chieh Chen, et al.
Published: (2024-12-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

Dietary and lifestyle indices for hyperinsulinemia and odds of MAFLD in overweight and obese children and adolescents
by: Ali Nikparast, et al.
Published: (2025-02-01)

FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease
by: Mário Reis Álvares-da-Silva, et al.
Published: (2025-01-01)

Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults
by: Jaejun Lee, et al.
Published: (2025-01-01)

Global research trends in Chinese medicine for the treatment of non-alcoholic fatty liver disease (NAFLD): A bibliometric study
by: Kangjie li, et al.
Published: (2025-03-01)

The effects of kefir drink on liver aminotransferases and metabolic indicators in patients with nonalcoholic fatty liver disease: a randomized controlled trial
by: Farzaneh Mohammadi, et al.
Published: (2025-01-01)

Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study
by: Hui Liu, et al.
Published: (2025-01-01)

The value of sex hormones and sex hormone-binding globulin in metabolic dysfunction-associated fatty liver disease among boys with obesity
by: Ying Wang, et al.
Published: (2025-02-01)

Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease
by: Doaa H. Hegazy, et al.
Published: (2024-06-01)

Association between neutrophil-to-high-density lipoprotein cholesterol ratio and non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease: evidence from NHANES 2017–2020
by: Na Zhu, et al.
Published: (2025-01-01)

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
by: Ewelina Jakielska, et al.
Published: (2023-03-01)

Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model
by: Sebastian Holländer, et al.
Published: (2025-01-01)

Association between the triglyceride-glucose index and liver fibrosis in adults with metabolism-related fatty liver disease in the United States: a cross-sectional study of NHANES 2017–2020
by: Yuou Ying, et al.
Published: (2025-01-01)

Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics
by: Jinliang Liang, et al.
Published: (2025-01-01)

NAFPD exacerbation by hyperlipidemia combined with hyperuricemia: a pilot rat experiment in lipidomics
by: Jingyun Li, et al.
Published: (2025-01-01)

Post-translational histone modifications associated with the development of metabolic dysfunction-associated fatty liver disease. Part 2. Histone methylation
by: O.E. Abaturov, et al.
Published: (2024-12-01)

Metabolic dysfunction-associated fatty liver disease and risk of nephrolithiasis: a sizeable cross-sectional study
by: Shengqi Zheng, et al.
Published: (2025-01-01)

A Summary of the Best Evidence for Wet Pack Management
by: Yi L, et al.
Published: (2025-01-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Genome-wide association study of the fatty liver index in the Taiwanese population reveals shared and population-specific genetic risk factors across ethnicities
by: Pei Pei Lau, et al.
Published: (2025-02-01)

Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis
by: George Koulaouzidis, et al.
Published: (2021-09-01)

Neuregulin1 ameliorates metabolic dysfunction-associated fatty liver disease via the ERK/SIRT1 signaling pathways
by: Chengan Xu, et al.
Published: (2025-01-01)

Summary of Evidence on Nutritional Management for Patients Undergoing Chemotherapy
by: Xin Dan, et al.
Published: (2024-12-01)

Consistency analysis of two US techniques for evaluating hepatic steatosis in patients with metabolic dysfunction-associated steatotic liver disease
by: Fei Chen, et al.
Published: (2025-01-01)

Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
by: Aleksey O. Bueverov
Published: (2019-03-01)

Dose-response relationship between the fatty liver index and asthma risk: NHANES 2001~2018
by: Tengfei Sun, et al.
Published: (2025-02-01)

Profile of Children With Non-alcoholic Fatty Liver Disease Referred to a Hospital in Iran
by: Amin Ghanbari, et al.
Published: (2024-12-01)

Association between Bioelectrical Impedance Parameters, Magnetic Resonance Imaging Muscle Parameters, and Fatty Liver Severity in Children and Adolescents
by: Kyungchul Song, et al.
Published: (2025-01-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality
by: Rosa Oh, et al.
Published: (2025-01-01)

Non-invasive methods for diagnosing portal hypertension and variceal bleeding due to liver cirrhosis secondary to NAFLD/MASLD: systematic review
by: Nebyu Yonas Shanka, et al.
Published: (2025-01-01)

Metabolic and Genetic Determinants of Lipid Metabolism Disruption in Non-Alcoholic Fatty Liver Disease
by: O. Yu. Kytikova, et al.
Published: (2020-05-01)

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
by: Melchor Alpízar Salazar, et al.
Published: (2025-01-01)